Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SNOA vs BMRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SNOA Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–2 Matrix Metrics)

SNOA Overall Winner 6-Pillar Tally: SNOA 5 – 0 BMRA (1 Tie) Matrix Metrics: SNOA 7 – 2 BMRA

As of Nov 16, 2026, Sonoma Pharmaceuticals, Inc. (SNOA) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SNOA carries a Unified Composite Score of 51.6/100 (HOLD) at $0.84 (46.1x Forward P/E, -3.3% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin).

  • Technical & Structure Timing Caution: SNOA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.2); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SNOA vs BMRA
SNOA NASDAQ Head-to-Head Winner
Sonoma Pharmaceuticals, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.84
-22.68% 1D
Market Cap $5.6M
TTM Revenue $23M
Forward P/E 46.1x
Beta / 30D Vol 1.39β · 78% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 49.0 Fund 52.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 34
RSI-14: 34.2 · SMA20: $1.13 · SMA50: $1.19
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96

6-Pillar Scorecard Institutional Category Breakdown (SNOA 5 – 0 BMRA)

Columns: Metric · SNOA · BMRA
1. Valuation Multiples SNOA
Forward P/E 46.1x N/M
Trailing P/E 46.1x N/M
PEG Ratio 1.08x N/M
EV / Revenue 0.2x 1.1x
2. Growth & Scale SNOA
Revenue Growth (YoY) +28.0% -8.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $23M $4.3M
Market Cap $5.6M $6.0M
3. Profitability & Quality SNOA
Gross Margin 39.2% 0.9%
Operating Margin -3.3% -125.2%
Net Profit Margin -7.6% -115.5%
Return on Equity (ROE) -34.5% -113.8%
4. Balance Sheet & Cash Flow SNOA
Cash Generation (TTM) -$4.1M -$3.2M
Cash Flow Margin -17.6% -73.5%
Net Cash / Leverage $1.6M Net Cash $1.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat SNOA
OpEx & R&D Intensity 42.5% of Rev ($10.0M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SNOA (7) vs BMRA (2)
Institutional Metric SNOA BMRA Criterion Row Edge
Market Capitalization
Scale
$5.6M $6.0M Larger Scale Tie
Trailing P/E Ratio
Valuation
46.1x N/M Lower Multiple SNOA
Forward P/E Ratio
Valuation
46.1x N/M Lower Multiple SNOA
Revenue Growth (YoY)
Growth
+28.0% -8.3% Higher Growth SNOA
Operating Margin (TTM)
Profitability
-3.3% -125.2% Higher Margin SNOA
Net Profit Margin
Profitability
-7.6% -115.5% Higher Margin SNOA
Return on Equity (ROE)
Capital Efficiency
-34.5% -113.8% Higher ROE SNOA
52-Week Range Position
Momentum
1% ($1–$4) 4% ($1–$3) Stronger Trend BMRA
Beta / 30D Volatility
Risk Regime
1.39β · 78% Vol 0.67β · 62% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
51.6 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite SNOA
Trailing 12M Revenue (USD)
Operating Scale
$23M $4.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
39.2% 0.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.08x PEG · 0.2x EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$4.1M ($1.6M Net Cash) -$3.2M ($1.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SNOA +3.44 pp
SNOA: -24.75% · BMRA: -28.19%
3M Horizon BMRA +18.2 pp
SNOA: -35.17% · BMRA: -16.97%
6M Horizon SNOA +22.79 pp
SNOA: -18.17% · BMRA: -40.96%
1Y Horizon BMRA +29.33 pp
SNOA: -76.19% · BMRA: -46.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SNOA Revenue BMRA Revenue SNOA Op. Margin BMRA Op. Margin Margin Leader
FY2019 $20M $10M -59.3% -46.4% BMRA
FY2020 $20M $10M -41.2% -41.0% BMRA
FY2021 $20M $10M -18.5% -104.2% SNOA
FY2022 $10M $20M -46.6% -24.0% BMRA
FY2023 $10M $10M -34.4% -135.3% SNOA
FY2024 $10M $10M -36.9% -117.6% SNOA
FY2025 $10M $10M -26.0% -96.7% SNOA
FY2026 $20M $0M -12.6% -119.5% SNOA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SNOA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNOA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SNOA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $5.6M market capitalization and -3.3% operating margin.
OpEx & R&D Reinvestment 42.5% of Rev ($10.0M)
90D Engineering Disclosures 0 Published
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SNOA vs BMRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Sonoma Pharmaceuticals, Inc. (SNOA) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SNOA carries a Unified Composite Score of 51.6/100 (HOLD) at $0.84 (46.1x Forward P/E, -3.3% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin). Technical & Structure Timing Caution: SNOA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.2); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SNOA leads the Growth & Scale pillar: SNOA posts +28.0% YoY revenue growth and +0.0% YoY earnings growth on $23M TTM revenue (39.2% gross margin, -3.3% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), SNOA cumulative revenue shifted +0.0% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, SNOA deploys 42.5% of Rev ($10.0M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.

SNOA screens cheaper on headline valuation multiples. SNOA trades at 46.1x Forward P/E, 46.1x Trailing P/E, 1.08x PEG, and 0.2x EV/Revenue (-17.6% FCF margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SNOA (-34.5% ROE) versus BMRA (-113.8% ROE) capital efficiency.

In options market volatility and institutional positioning, SNOA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.39β · 78% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.